Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products. Its only currently marketed product is ARCALYST® (rilonacept) for Cryopyrin-Associated Periodic Syndromes (CAPS). The company maintains significant strategic collaborations with sanofi-aventis (aflibercept and antibody discovery) and Bayer HealthCare (VEGF Trap-Eye).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|---|
| Total Revenues | $60,653 | $117,036 | $37,983 |
| Net Loss | $(18,459) | $(30,077) | $(56,691) |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(0.38) | $(0.86) |
| Operating Expenses | $80,042 | $152,336 | $102,236 |
| Research & Development Expenses | $66,577 | $127,847 | $85,099 |
| Cash and Cash Equivalents (Balance Sheet) |
$292,129 (as of June 30, 2008) | ||
| Marketable Securities (Total) |
$450,714 (as of June 30, 2008) | ||
| Notes Payable (Current Portion) |
$118,653 (as of June 30, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the six months ended June 30, 2008, increased to $117.0 million from $38.0 million in the prior year period. This 208% increase was driven primarily by higher contract research and development revenue from sanofi-aventis ($74.3 million vs. $25.3 million) and Bayer HealthCare ($19.2 million vs. $0), as well as technology licensing revenue ($20.0 million vs. $8.4 million).
- Net Loss Reduction: Net loss improved significantly to $30.1 million for the first half of 2008 compared to $56.7 million in the same period of 2007. The improvement was due to increased revenue from collaborations, partially offset by higher operating expenses.
- Expense Increases: Research and development expenses rose to $127.8 million (six months 2008) from $85.1 million (six months 2007). This increase was attributed to higher clinical trial costs (specifically for VEGF Trap-Eye and ARCALYST), increased payroll due to headcount growth (average headcount increased to 742 from 602), and cost-sharing of Bayer HealthCare's VEGF Trap-Eye development expenses ($15.4 million).
- Debt Repurchase: In the second quarter of 2008, the company repurchased $81.3 million in principal amount of its 5.5% Convertible Senior Subordinated Notes for $82.1 million, recognizing a $0.9 million loss on early extinguishment of debt. Remaining notes payable total $118.7 million.
Guidance, Outlook, and Risks
- ARCALYST Commercialization: ARCALYST was launched in March 2008. The company shipped $2.4 million in the first half of 2008 but recognized no product sales revenue due to accounting rules regarding returns and rebates. Deferred revenue related to ARCALYST totaled $2.3 million. Management projects total shipments of approximately $10 million for 2008 but does not expect commercialization to materially impact cash flows in 2008 due to the rarity of the disease.
- Clinical Pipeline:
- Aflibercept (Oncology): Four Phase 3 trials are ongoing in collaboration with sanofi-aventis. A Phase 2 single-agent study in ovarian cancer did not meet its primary endpoint.
- VEGF Trap-Eye (Ophthalmology): Two Phase 3 trials (VIEW 1 and VIEW 2) are underway for wet AMD. Positive 32-week data from a Phase 2 study was reported.
- Antibody Program: REGN88 (IL-6R) is in Phase 1 for rheumatoid arthritis. The company plans to file an IND for a Dll4 antibody by the end of 2008.
- Liquidity and Capital Resources: As of June 30, 2008, the company held $744.5 million in cash, cash equivalents, and marketable securities. Management believes existing resources, including collaboration funding, will meet operating needs through at least 2012.
- Key Risks:
- Debt Maturity: $118.7 million of convertible debt matures in October 2008. If the stock price is below the conversion price ($30.25) at maturity, the company must repay the principal in cash.
- Collaboration Dependence: Significant reliance on sanofi-aventis and Bayer HealthCare for funding and commercialization of key pipeline assets.
- Regulatory and Clinical Uncertainty: Risks associated with the failure of clinical trials or inability to obtain regulatory approval for product candidates.
- Intellectual Property: Potential infringement claims from third parties (e.g., Genentech, Roche) regarding VEGF Trap and IL-6R technologies.
- Unusual Items: In July 2008, the company resolved a dispute with Cellectis S.A. via an amended license agreement, making a $12.5 million non-refundable payment and agreeing to low single-digit royalties. $1.6 million of this expense was accrued at June 30, 2008.
Investor Verification Checklist
- Debt Conversion Status: Verify the market price of Regeneron's common stock relative to the $30.25 conversion price of the remaining $118.7 million convertible notes maturing in October 2008 to assess cash repayment risk.
- ARCALYST Revenue Recognition: Monitor future filings for the timing of revenue recognition from ARCALYST shipments, as current shipments are deferred due to lack of historical return/rebate data.
- Clinical Trial Outcomes: Track enrollment and interim results for the four Phase 3 aflibercept trials and the two Phase 3 VEGF Trap-Eye trials, as these are critical for future milestone payments and commercialization.
- Cellectis Agreement Impact: Review the amortization schedule and royalty obligations associated with the new $12.5 million Cellectis license payment.
- Cash Burn Rate: Analyze the trend in net cash used in operating activities ($11.7 million for six months 2008) against the $744.5 million cash balance to confirm the runway through 2012.